Recall the adult stem cell myoblast program ? This cell therapy was for the ' treatment of chronic heart failure, advanced cardiac disease, myocardial infection and ischemia.'
"Although our adult stem cell myoblast program has been approved for a Phase II clinical trial, we have suspended that program indefinitely due to a lack of funding. As a result of our emphasis on our retinal program, our hemangioblast program and our blastomere program, our ability to progress as a company is more significantly hinged on the success of fewer programs and thus, a setback or adverse development relating to any one of them could potentially have a significant impact on share price as well as an inhibitory effect on our ability to raise additional capital................ If we are unable to develop our technologies, investors will likely lose their entire investment in us."
As filed with the Securities and Exchange Commission on October 20, 2011
Reg. No. 333-175019. POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
"The Phase I trials were conducted on a myoblast stem cell therapy involving transplantation of expanded autogolous myoblast (adult progenitor stem cells) derived from a small biopsy of skeletal muscle in the leg. The technology allows for expansion of the myoblast into hundreds of millions of cells over the course of two to three weeks. The surplus is then transplanted back into the patient's scarred heart tissue. The transplanted cells are incorporated into the muscle tissue, are entrained in the beat of the heart, and from preliminary data, appear to also enhance revascularization of the infarcted area."
"Data collected from the trials suggests that the transplanted myoblast often improve heart function, and can lead to a significant improvement in quality of life for the patient. In the Phase 1b study, the company was able to score patients using the New York Heart Association Quality of life test, and the average observed improvement was significantly better than typical standard of care therapies in use today. According to the National Institute of Health, approximately five million people suffer from congestive heart failure, with an estimated 400,000 new cases diagnosed each year. Of the total number afflicted with the disease, 50% will die due to related complications within five years."
"The market potential in the EU is even greater than in the U.S. by up to 50% in patient population size by some estimates."
Yeah, regenerative medicine is mankinds' panacea to what is ailing you. Ain't that right, ACTC sheeples ?